A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice

Journal of Immunology

Volumn 162, Issue 2, 1999, Pages 753-760

  Raja Gabaglia, Claudia ^a   Pedersen, Brian ^a   Hitt, Mary ^b   Burdin, Nicolas ^a   Sercarz, Eli E ^a   Graham, Frank L ^b   Gauldie, Jack ^b   Braciak, Todd A ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IMMUNOMODULATION; INFECTION RESISTANCE; INTERFERON PRODUCTION; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD45; DISEASE SUSCEPTIBILITY; EXTREMITIES; GENETIC VECTORS; HOST-PARASITE RELATIONS; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPH NODES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SPLENIC DISEASES; VACCINES, SYNTHETIC;

EID: 0345222527     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Locksley, R. M., and P. Scott. 1991. Helper T-cell subsets in mouse leishmaniasis: induction, expansion and effector function. Immunol. Today 12:A58.
2. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151.
3. Reed, S. G., and P. Scott. 1993. T-cell and cytokine responses in leishmaniasis. Curr. Opin. Immunol. 5:524.
4. Afonso, L. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235.
5. Heinzel, F. P., R. M. Rerko, F. Ahmed, and E. Pearlman. 1995. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J. Immunol. 155:730.
6. Sypek, J. P., C. L. Chung, S. E. Mayor, J. M. Subramanyam, S. J. Goldman, D. S. Sieburth, S. F. Wolf, and R. G. Schaub. 1993. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1797.
7. Braciak, T. A., S. K. Mittal, F. L. Graham, C. D. Richards, and J. Gauldie. 1993. Construction of recombinant human type 5 adenoviruses expressing rodent IL-6 genes: an approach to investigate in vivo cytokine function. J. Immunol. 151: 5145.
8. Addison, C. L., J. Gauldie, W. J. Muller, and F. L. Graham. 1995. An adenoviral vector expressing Interleukin-4 modulates tumorigenicity and induces regression in a murine breast cancer model. Int. J. Oncol. 7:1253.
9. Bramson, J., M. Hitt, W. S. Gallichan, K. L. Rosenthal, J. Gauldie, and F. L. Graham. 1996. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum. Gene Ther. 7:333.
10. Bett, A. J., W. Haddara, L. Prevec, and F. L. Graham. 1994. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA 91:8802.
11. Aebischer, T., L. Morris, and E. Handman. 1994. Intravenous injection of irradiated Leishmania major into susceptible BALB/c mice: immunization or protective tolerance. Int. Immunol. 6:1535.
12. + T cell subset expression. Int. Immunol. 6:785.
13. Belosevic, M., D. S. Finbloom, P. H. Van Der Meide, M. V. Slayter, and C. A. Nacy. 1989. Administration of monoclonal anti-IFN-γ antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J. Immunol. 143:266.
14. Sadick, M. D., N. Street, T. R. Mosmann, and R. M. Locksley. 1991. Cytokine regulation of murine leishmaniasis: interleukin 4 is not sufficient to mediate progressive disease in resistant C57BL/6 mice. Infect. Immun. 59:4710.
15. Chatelain, R., K. Varkila, and R. L. Coffman. 1992. IL-4 induces a Th2 response in Leishmania major-infected mice. J. Immunol. 148:1182.
16. + T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 6:541.
17. Gessner, A., A. Will, M. Vieth, K. Schroppel, and M. Rollinghoff. 1995. Stimulation of B-cell lymphopoiesis by interleukin-7 leads to aggravation of murine leishmaniasis. Immunology 84:416.
18. Scott, P., and G. Trinchieri. 1995. The role of natural killer cells in host-parasite interactions. Curr. Opin. Immunol. 7:34.
19. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137.
20. Laskay, T., A. Diefenbach, M. Rollinghoff, and W. Solbach. 1995. Early parasite containment is decisive for resistance to Leishmania major infection [published erratum appears in 1995 Eur. J. Immunol. 25:2726.]. Eur. J. Immunol. 25:2220.
21. Laskay, T., A. Diefenbach, M. Rollinghoff, and W. Solbach. 1995. Early parasite containment is decisive for resistance to Leishmania major infection [published erratum appears in 1995 Eur. J. Immunol. 25:2726.]. Eur. J. Immunol. 25:2220.
22. Gately, M. K., B. B. Desai, A. G. Wolitzky, P. M. Quinn, C. M. Dwyer, F. J. Podlaski, P. C. Familletti, F. Sinigaglia, R. Chizzonnite, U. Gubler, et al. 1991. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol. 147:874.
23. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827.
24. Launois, P., K. G. Swihart, G. Milon, and J. A. Louis. 1997. Early production of IL-4 in susceptible mice infected with Leishmania major rapidly induces IL-12 unresponsiveness. J. Immunol. 158:3317.
25. Tare, N. S., S. Bowen, R. W. Warrier, D. M. Carvajal, W. R. Benjamin, J. H. Riley, T. D. Anderson, and M. K. Gately. 1995. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J. Interferon Cytokine Res. 15:377.
26. Sarmiento, U. M., J. H. Riley, P. A. Knaack, J. M. Lipman, J. M. Becker, M. K. Gately, R. Chizzonite, and T. D. Anderson. 1994. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab. Invest. 71:862.
27. Gately, M. K., R. R. Warrier, S. Honasoge, D. M. Carvajal, D. A. Faherty, S. E. Connaughton, T. D. Anderson, U. Sarmiento, B. R. Hubbard, and M. Murphy. 1994. Administration of recombinant IL-I2 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol. 6:157.
28. Cohen, J. 1995. IL-12 deaths: explanation and a puzzle. Science 270:908.
29. Scott, P., A. Eaton, W. C. Gause, X. di Zhou, and B. Hondowicz. 1996. Early IL-4 production does not predict susceptibility to Leishmania major. Exp. Parasitol. 84:178.
30. Lezama-Davila, C. M., D. M. Williams, G. Gallagher, and J. Alexander. 1992. Cytokine control of Leishmania infection in the BALB/c mouse: enhancement and inhibition of parasite growth by local administration of IL-2 or IL-4 is species and time dependent. Parasite Immunol. 14:37.
31. Lamont, A. G., and L. Adorini. 1996. IL-I2: a key cytokine in immune regulation. Immunol. Today 17:214.
32. Rossi-Bergmann, B., I. Muller, and E. B. Godinho. 1993. TH1 and TH2 T-cell subsets are differentially activated by macrophages and B cells in murine leishmaniasis. Infect. Immun. 61:2266.
33. Sacks, D. L., P. A. Scott, R. Asofsky, and F. A. Sher. 1984. Cutaneous leishmaniasis in anti-IgM-treated mice: enhanced resistance due to functional depletion of a B cell-dependent T cell involved in the suppressor pathway. J. Immunol. 132:2072.
34. Hoerauf, A., M. Rollinghoff, and W. Solbach. 1996. Co-transfer of B cells converts resistance into susceptibility in T cell-reconstituted. Leishmania major-resistant C.B-17 scid mice by a non-cognate mechanism. Int. Immunol. 8:1569.
35. Bramson, J. L., M. Hitt, C. L. Addison, W. J. Muller, J. Gauldie, and F. L. Graham. 1996. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther. 7:1995.
36. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gonczol, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits E1 -deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407.
37. Bramson, J. L., F. L. Graham, and J. Gauldie. 1995. The use of adenoviral vectors for gene therapy and gene transfer in vivo. Curr Opin. Biotechnol. 6:590.
38. Haddada, H., L. Cordier, and M. Perricaudet. 1995. Gene therapy using adenovirus vectors. Curr. Top. Microbiol. Immunol. 199:297.
39. Graham, F. L. 1990. Adenoviruses as expression vectors and recombinant vaccines. Trends Biotechnol. 8:85.
40. Graham, F. L., and L. Prevec. 1992. Adenovirus-based expression vectors and recombinant vaccines. Biotechnology 1992:20:363.
41. Prevec, L., J. B. Campbell, B. S. Christie, L. Belbeck, and F. L. Graham. 1990. A recombinant human adenovirus vaccine against rabies. J. Infect. Dis. 161:27.
42. Prevec, L., B. S. Christie, K. E. Laurie, M. M. Bailey, F. L. Graham, and K. L. Rosenthal 1991. Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J. Acquired Immune Defic. Syndr. 4:568.
43. Addison, C. L., T. Braciak, R. Ralston, W, J. Muller, J. Gauldie, and F. L. Graham. 1995. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. USA 92:8522.
44. Nabors, G. S., L. C. Afonso, J. P. Farrell, and P. Scott. 1995. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc. Natl. Acad. Sci. USA 92:3142.